Year: 2018
Type: review
Abstract: Immune checkpoint inhibitors (ICIs) have recently revolutionized cancer treatment, providing unprecedented clinical benefits. However, primary or acquired therapy resistance can affect up to two-thirds of patients receiving ICIs, underscoring the urgency to elucidate the mechanisms of treatment resistance and to design more effective therapeutic strategies. Conventional cancer treatments, including cytotoxic chemotherapy, radiation therapy, and targeted therapy, have immunomodulatory effects in addition to direct cancer cell-killing activities. Their clinical utilities in combination with ICIs have been explored, aiming to achieve synergetic effects with improved and durable clinical response. Here, we will review the immunomodulatory effects of chemotherapy, targeted therapy, and radiation therapy, in the setting of ICI, and their clinical implications in reshaping modern cancer immunotherapy.
Source: Frontiers in Immunology
Institutions: Mayo Clinic, Mayo Clinic in Florida
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
Awards: Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS), Role of Bim and soluble B7-H1 in monitoring T cell responses to anti-PD-1 therapy in melanoma, Functional B7-H1 expressed by T cells, A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABR, Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic, Training Grant in Clinical Pharmacology
OpenAlex ID: W2884976231
